The companies anticipate finalising the acquisition in the third quarter of 2026.

Under the agreement, Servier will pay $1.55 billion upfront, with up to an additional $1.1 billion tied to regulatory and ...

Edgewise Therapeutics (EWTX) stays a Buy after its $2.65B Servier deal funds EDG-7500 for HCM with key Q2 2026 data. Read ...

By Siddhi Mahatole and Bhanvi Satija June 1 (Reuters) - Edgewise Therapeutics on Monday agreed to sell its muscular dystrophy drug and related business to Servier in a deal worth up to $2.65 billion, ...

The French pharma firm Servier is buying an experimental muscular dystrophy drug from Edgewise Therapeutics for $1.55 billion ...

In addition to the upfront fee, Servier has committed up to $1.1 billion in regulatory and commercial milestones to acquire ...

The French drugmaker has agreed to acquire an experimental tablet from Edgewise Therapeutics that some bullish analysts say ...

Muscular dystrophy (MD) is a group of genetic diseases that cause your muscles to progressively weaken and degenerate. There are several types of MD, each with its own symptoms, but they all involve ...

The first gene therapy for children with Duchenne muscular dystrophy has been approved by the U.S. Food and Drug Administration. The therapy can be used in 4- and 5-year-olds with the degenerative ...

Investigational oral substrate therapy BBP-418 demonstrated significant increases in alpha-dystroglycan glycosylation and improved ambulatory function in the phase 3 FORTIFY interim analysis.

Your muscles need continuous maintenance to stay strong and healthy. Duchenne muscular dystrophy (DMD) happens when there is a change in a person's genetic instructions that affects the production of ...